Opinion

Video

The Goals of AML Maintenance Therapy

Catherine E. Lai, MD, MPH, discusses the goals of maintenance therapy, how to manage treatment-related adverse events, and the impact of treatment on patient’s quality of life.

Transcript:

For patients who aren’t able to go to transplant, the goal of therapy is to continue maintenance if that is an option for them to prevent leukemia relapse. We try to keep patients on therapy for as long as they can tolerate it with regard to adverse effects, particularly in terms of quality of life and cytopenias. That is the main concern for patients. There are some GI adverse effects as well. These are all typically manageable and can be alleviated by either dose interruptions or dose holds or decreasing the duration. But it’s important to try to continue the maintenance and just modify your maintenance treatment accordingly so that patients can continue on therapy.

Transcript edited for clarity.

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study